Lilly's Kevin Duffin reported epigenetic clocks advancing slower in 71 Surmount V participants over 50. Outside experts caution the research is early and lacks a placebo group.
Recap by typeshit. Full story at CNN.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Facebook post says very few people get Ozempic for free and calls the drug effective for health. The claim is the poster's own, with no detail given.
In a 575-user study across four countries, 39% reported nails lifting versus 9% of controls. A companion study also found more hair loss and scalp redness.
Loading…